{"id":"NCT05139810","sponsor":"Ionis Pharmaceuticals, Inc.","briefTitle":"OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)","officialTitle":"A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients With Hereditary Angioedema (HAE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-03","primaryCompletion":"2023-11-09","completion":"2023-11-09","firstPosted":"2021-12-01","resultsPosted":"2025-03-06","lastUpdate":"2025-03-06"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema"],"interventions":[{"type":"DRUG","name":"Donidalorsen","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pooled Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Cohort A: Donidalorsen 80 mg","type":"EXPERIMENTAL"},{"label":"Cohort B: Donidalorsen 80 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the safety and efficacy of donidalorsen in participants with HAE and effect of donidalorsen on the quality and pattern of HAE attacks and their impact on quality of life (QoL).","primaryOutcome":{"measure":"Time-Normalized Investigator-Confirmed (IC) HAE Attack Rate (Per Month) From Week 1 to Week 25","timeFrame":"Week 1 to Week 25","effectByArm":[{"arm":"Pooled Placebo","deltaMin":2.26,"sd":null},{"arm":"Cohort A: Donidalorsen 80 mg","deltaMin":0.44,"sd":null},{"arm":"Cohort B: Donidalorsen 80 mg","deltaMin":1.02,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"=0.004"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":51,"countries":["United States","Belgium","Bulgaria","Canada","Denmark","France","Germany","Israel","Italy","Netherlands","Poland","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["38819395"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":22},"commonTop":["Nasopharyngitis","Headache","Influenza","Upper Respiratory Tract Infection","Injection Site Erythema"]}}